FDA approved Cablivi in 2019 for usage in adults with acquired thrombocytopenic purpura (autoimmune blood disorder), and this…

Eculizumab is indicated for treatment of patients with paroxysmal nocturnal hemoglobinuria to reduce hemolysis, atypical hemolytic uremic syndrome…